CD8A and neoplasm: Figure 4A displays survival curves by molecular subtype stratified by CD8 status, with LB in Figure 4B. This result was also observed in an MVA of luminal tumours only, making up 84% of the cohort, where the final resolved model included CD8 (HR 2.2, CI 1.2–3.9, p = 0.008) age of <50, margin status and radiotherapy boost (Table S4). MVA of TNBC showed none of the immune markers to be prognostically significant for LR, only cavity boost status (Table S5; HR 9.9; 1.2–80.9, p = 0.032).